Perioperative management of SGLT2 inhibitors: balancing euglycaemic ketoacidosis risk and cardiorenal benefits.

IF 4.7
Keqin Ji, Dongmei Zhang, Yun Zhao, Zhun Zeng, Min Jiang, Jianping Zhang
{"title":"Perioperative management of SGLT2 inhibitors: balancing euglycaemic ketoacidosis risk and cardiorenal benefits.","authors":"Keqin Ji, Dongmei Zhang, Yun Zhao, Zhun Zeng, Min Jiang, Jianping Zhang","doi":"10.1016/j.diabet.2026.101793","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies for type 2 diabetes, heart failure, and chronic kidney disease, creating a perioperative need to balance prevention of euglycaemic diabetic ketoacidosis (euDKA) against cardiorenal protection. Fasting, surgical stress, infection, reduced carbohydrate intake, insulin dose reduction, and hypovolaemia can amplify glycosuria and ketogenesis and precipitate euDKA. Most guidelines recommend withholding SGLT2 inhibitors for 3-4 days before elective surgery, although recommendations vary by agent, procedure, fasting duration, diabetes status, and monitoring capacity. Emerging evidence indicates competing perioperative risks and benefits. Inadequate withholding and emergency surgery are associated with high-anion-gap metabolic acidosis and ketoacidosis, whereas observational studies associate preoperative use with lower risks of acute kidney injury and short-term mortality. Heart failure withdrawal studies further suggest that cardiovascular and volume-regulatory benefits may diminish rapidly after interruption. These findings challenge uniform withholding but do not support routine perioperative continuation. Management should be stratified by treatment indication, glycated haemoglobin, insulin dependence, hepatic and kidney function, infection and volume status, surgical urgency and invasiveness, expected fasting duration, and access to ketone and acid-base monitoring. Patients at high metabolic risk generally require an adequate preoperative withholding interval and intensified monitoring, whereas low-risk patients treated primarily for heart failure or chronic kidney disease require individualised multidisciplinary assessment. Future studies should define indication- and risk-based withholding and restart strategies and jointly evaluate euDKA, acute kidney injury, worsening heart failure, myocardial injury, mortality, and postoperative recovery.</p>","PeriodicalId":101305,"journal":{"name":"Diabetes & metabolism","volume":" ","pages":"101793"},"PeriodicalIF":4.7000,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.diabet.2026.101793","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies for type 2 diabetes, heart failure, and chronic kidney disease, creating a perioperative need to balance prevention of euglycaemic diabetic ketoacidosis (euDKA) against cardiorenal protection. Fasting, surgical stress, infection, reduced carbohydrate intake, insulin dose reduction, and hypovolaemia can amplify glycosuria and ketogenesis and precipitate euDKA. Most guidelines recommend withholding SGLT2 inhibitors for 3-4 days before elective surgery, although recommendations vary by agent, procedure, fasting duration, diabetes status, and monitoring capacity. Emerging evidence indicates competing perioperative risks and benefits. Inadequate withholding and emergency surgery are associated with high-anion-gap metabolic acidosis and ketoacidosis, whereas observational studies associate preoperative use with lower risks of acute kidney injury and short-term mortality. Heart failure withdrawal studies further suggest that cardiovascular and volume-regulatory benefits may diminish rapidly after interruption. These findings challenge uniform withholding but do not support routine perioperative continuation. Management should be stratified by treatment indication, glycated haemoglobin, insulin dependence, hepatic and kidney function, infection and volume status, surgical urgency and invasiveness, expected fasting duration, and access to ketone and acid-base monitoring. Patients at high metabolic risk generally require an adequate preoperative withholding interval and intensified monitoring, whereas low-risk patients treated primarily for heart failure or chronic kidney disease require individualised multidisciplinary assessment. Future studies should define indication- and risk-based withholding and restart strategies and jointly evaluate euDKA, acute kidney injury, worsening heart failure, myocardial injury, mortality, and postoperative recovery.

SGLT2抑制剂的围手术期管理:平衡血糖酮症酸中毒风险和心肾益处
钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂是2型糖尿病、心力衰竭和慢性肾脏疾病的既定治疗方法,这使得围手术期需要平衡预防血糖性糖尿病酮症酸中毒(euDKA)和心肾保护。禁食、手术应激、感染、碳水化合物摄入减少、胰岛素剂量减少和低血容量可增加糖尿和生酮并沉淀euDKA。大多数指南建议在择期手术前3-4天不使用SGLT2抑制剂,尽管建议因药物、手术、禁食时间、糖尿病状态和监测能力而异。新出现的证据表明围手术期风险和收益相互竞争。不充分的保留和急诊手术与高阴离子间隙代谢性酸中毒和酮症酸中毒有关,而观察性研究表明术前使用可降低急性肾损伤和短期死亡率的风险。心力衰竭戒断研究进一步表明,中断后心血管和容量调节益处可能迅速减少。这些发现挑战了统一的保留,但不支持常规的围手术期延续。治疗应根据治疗指征、糖化血红蛋白、胰岛素依赖、肝肾功能、感染和容量状况、手术紧迫性和侵入性、预期禁食时间、酮和酸碱监测进行分层。高代谢风险患者通常需要适当的术前停药间隔和加强监测,而主要治疗心力衰竭或慢性肾脏疾病的低风险患者则需要个性化的多学科评估。未来的研究应明确基于适应症和风险的停药和重启策略,并联合评估euDKA、急性肾损伤、心衰恶化、心肌损伤、死亡率和术后恢复。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书